Dalcetrapib
A review links the B1B1 CETP genotype to higher CETP activity, lower HDL cholesterol, and more pronounced postprandial lipemia (Curr Med Chem 2009)
Original title: Cholesterol ester transfer protein (CETP), postprandial lipemia and hypolipidemic drugs
This review examines the role of cholesteryl ester transfer protein (CETP) in HDL metabolism, reverse cholesterol transport, and postprandial lipemia. In the hypertriglyceridemic state, CETP is highly expressed and reverse cholesterol transport favors formation of small dense LDL and small dense HDL, both implicated in atherosclerosis progression. Several, though not all, studies reported that the B1B1 CETP genotype is associated with higher plasma CETP concentration or activity and lower HDL cholesterol, and the magnitude of postprandial lipemia is linked to plasma CETP concentration and lipoprotein content and size. The review discusses synthetic CETP inhibitors evaluated in animals (CGS25159 and JTT-705) and in humans (JTT-705 and torcetrapib), noting that torcetrapib raised blood pressure and produced other off-target effects, and questions whether HDL generated during torcetrapib treatment remains fully bioactive.
Original abstract
Cholesterol ester transfer protein (CETP) plays a significant role in high density lipoprotein (HDL) metabolism and reverse cholesterol transport (RCT). A reduction in CETP activity leads to an increase in HDL-cholesterol levels. However, the relationship between reduced CETP function and atherosclerosis is complex and confusing. In the hypertriglyceridemic state, CETP is highly expressed and RCT leads to the formation of small dense low density lipoprotein (LDL) and small dense HDL, both of which are involved in the progression of atherosclerosis. Significant associations of the B1B1 genotype with higher plasma CETP concentration and/or CETP activity and lower HDL cholesterol were reported in several, but not all, studies. The magnitude of postprandial lipemia is also associated with plasma CETP concentration and lipoprotein content and size. Several conditions such as metabolic syndrome, hypertension, insulin resistance, obesity and familial hypercholesterolaemia are characterized by a more pronounced postprandial hypertriglyceridemia and delayed TG clearance than normal states. Thus, CETP is considered as a candidate target for drug therapy. A number of synthetic CETP inhibitors (CGS25159 and JTT-705) were evaluated in animals with satisfactory results. In humans, two CETP inhibitors were evaluated, JTT-705 and torcetrapib, leading to HDL increase. However, torcetrapib administration was associated with an increase in blood pressure and other "off-target" effects. It is also not clear whether the HDL produced during treatment with torcetrapib is bioactive (i.e. an "on target" undesirable action). In the current review, CETP function regarding lipid metabolism (in fasting and fed states) from human and animal studies as well as the current knowledge on CETP inhibitors are discussed. We also discuss gender influence on the action of hypolipidemic drugs and their effect on CETP mass and activity, as well as on the lipid profile.
dalcetrapibHDL biologymechanismstorcetrapib
Summary written by cetpinhibition.org from the published abstract; figures as published. Page updated 18 August 2026. Methods.